VRCA (Verrica Pharmaceuticals) Change In Payables And Accrued Expense : $-2.36 Mil (TTM As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Verrica Pharmaceuticals Change In Payables And Accrued Expense?

Verrica Pharmaceuticals's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was $0.52 Mil. It means Verrica Pharmaceuticals's Accounts Payable & Accrued Expense increased by $0.52 Mil from Dec. 2024 to Mar. 2025 .

Verrica Pharmaceuticals's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was $-0.86 Mil. It means Verrica Pharmaceuticals's Accounts Payable & Accrued Expense declined by $0.86 Mil from Dec. 2023 to Dec. 2024 .

Verrica Pharmaceuticals Change In Payables And Accrued Expense Historical Data

The historical data trend for Verrica Pharmaceuticals's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verrica Pharmaceuticals Change In Payables And Accrued Expense Chart

Verrica Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

0.56

0.71

-0.59

13.49

-0.86

Verrica Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															2.02	0.64	0.73	-4.25	0.52

Verrica Pharmaceuticals Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.36 Mil.

Verrica Pharmaceuticals Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Verrica Pharmaceuticals's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Verrica Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verrica Pharmaceuticals Inc (NAS:VRCA) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

1NE:Germany

Address

44 West Gay Street, Suite 400, West Chester, PA, USA, 19380

Website

https://www.verrica.com

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

Executives

Christopher G. Hayes	officer: General Counsel	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Ted White	director, officer: President and CEO	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Terry Kohler	officer: Chief Financial Officer	C/O VERRICA PHARMACEUTICALS INC., 44 WEST GAY STREET, SUITE 400, WEST CHESTER PA 19380
Joe Bonaccorso	officer: Chief Commercial Officer	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Gary Goldenberg	director	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Paul B Manning	director, 10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
A Brian Davis	officer: Chief Financial Officer	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Craig Ballaron	director	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Stalfort John A Iii	director	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Lawrence Eichenfield	director	C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502
Diem Nguyen	director	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Matt Davidson	10 percent owner	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Linda Palczuk	officer: Chief Operating Officer	7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046
Chris Degnan	officer: Chief Financial Officer	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380